NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolled
NuCana plc reports the Phase Ib/II NuTide:303 study of NUC-3373 combinations was terminated at the sponsor's discretion, with results posted July 23, 2026.
NuCana plc's registry update this week centers on the closure of its multi-arm NuTide:303 trial studying NUC-3373 combinations in advanced solid tumors.
- The Phase Ib/II study "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours" (NCT05714553, NuTide:303) was terminated, with the sponsor stating the NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.1
- Enrollment reached 19 participants across two modules: Module 1 combined NUC-3373 + leucovorin (LV) in combination with pembrolizumab for the treatment of patients with advanced/metastatic solid tumours who have progressed on ≤2 prior therapies for metastatic disease1, while Module 2 tested NUC-3373 + LV in combination with docetaxel for the treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC) or pleural mesothelioma who have progressed on, or were unable to tolerate, 1 or 2 prior lines of cytotoxic chemotherapy-containing regimens for advanced/metastatic disease.1
- Primary completion and study completion are both listed as actual dates of May 30, 2025, and results were first posted July 23, 2026, alongside the last update on the same date.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.